Dual Antiplatelet Therapy in Coronary Artery Disease

Autor:	Yogesh Belagali, Prathap Kumar, Raghav Sharma, S. P. Prashanth
Rok vydání:	2020
Předmět:	Ticagrelor medicine.medical_specialty Acute coronary syndrome animal structures Prasugrel Percutaneous Review 030204 cardiovascular system & hematology Coronary artery disease 03 medical and health sciences 0302 clinical medicine Switching between antiplatelets Internal medicine Diseases of the circulatory (Cardiovascular) system Medicine In patient cardiovascular diseases 030212 general & internal medicine business.industry medicine.disease Clopidogrel RC666-701 Dual antiplatelet therapy Conventional PCI Cardiology Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Cardiology and Therapy Cardiology and Therapy, Vol 9, Iss 2, Pp 349-361 (2020)
ISSN:	2193-6544 2193-8261
DOI:	10.1007/s40119-020-00197-0
Popis:	Acute coronary syndrome (ACS) is principally driven by platelet aggregation. Dual antiplatelet therapy (DAPT) has demonstrated a reduction in recurrent ischemic events. The newer antiplatelets ticagrelor and prasugrel have demonstrated superiority over clopidogrel. While prasugrel demonstrated benefit in patients scheduled for percutaneous intervention (PCI), benefits of ticagrelor were seen irrespective of the treatment strategy. Current guidelines recommend the use of DAPT for 1 year in all patients with ACS. Ticagrelor 60 mg is recommended for up to 3 years in high-risk patients. DAPT and Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE DAPT) scores are tools to support decision-making in deciding duration of dual antiplatelet therapy. Electronic supplementary material The online version of this article (10.1007/s40119-020-00197-0) contains supplementary material, which is available to authorized users.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff4b257f855e4325d31d4a193cb95fc https://doi.org/10.1007/s40119-020-00197-0 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.